Investor Relations

Press Releases

Date Title and Summary View
Toggle Summary NanoString Technologies to Release Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call on Wednesday, March 7, 2018
SEATTLE , Feb. 21, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release fourth quarter and fiscal year 2017 financial results after the close
View HTML
Toggle Summary NanoString Showcases Groundbreaking New Platforms at 2018 Advances in Genome Biology and Technology (AGBT) Conference
Digital Spatial Profiling Demonstrates Profiling of Proteins and 1,000+ mRNAs Across Multiple Regions from FFPE Tissue Sections using Next Generation Sequencing Readout First Customer Data Using Hyb & Seq Single Molecule Sequencing Demonstrates Potential Utility in Oncology and Infectious Disease
View HTML
Toggle Summary NanoString Announces Largest and Most Comprehensive Study to Date of Prosigna Breast Cancer Assay Published in Journal of Clinical Oncology
Comprehensive Study Includes All Danish Women Diagnosed with Breast Cancer from 2000 to 2003 who were Indicated for Prosigna and Treated with Endocrine Therapy Accompanying Editorial Highlights Encouraging Data on Clinical Utility in Node-Positive Breast Cancer SEATTLE , Feb.
View HTML
Toggle Summary NanoString Reports Inducement Grant Under NASDAQ Listing Rules
SEATTLE , Jan. 19, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported, as required by NASDAQ Stock Market Rules, equity inducement awards to Thomas Bailey , NanoString's
View HTML
Toggle Summary NanoString Appoints Thomas Bailey as Chief Financial Officer
SEATTLE , Jan. 16, 2018 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced that Thomas Bailey has been appointed chief financial officer, effective January 16, 2018 .    Mr.
View HTML
Toggle Summary NanoString Technologies Provides Preliminary Operational and Financial Results for Fourth Quarter and Fiscal Year 2017
Fourth Quarter Product and Service Revenue Exceeds High End of Company Guidance
View HTML
Toggle Summary NanoString and RikenGenesis Announce Partnership to Commercialize nCounter-Based Diagnostic Assays in Japan
NanoString and Riken Genesis, a subsidiary of Sysmex, partner to register and commercialize NanoString's Lymphoma Subtyping Test for diagnostic use in Japan
View HTML
Toggle Summary NanoString Technologies Highlights Advances in Precision Oncology at the 59th Annual Meeting of the American Society of Hematology
More than 45 Abstracts Highlight the Value of the nCounter Platform in Hematology, including 11 that Demonstrate the Potential Clinical Utility of the Lymphoma Subtyping Test Company Announces Launch of Vantage 3D DNA:RNA:Protein Hematology Assays SEATTLE , Dec.
View HTML
Toggle Summary NanoString Highlights Record Number of nCounter-Based Research Abstracts at the 2017 Annual Meeting of the Society of Immunotherapy of Cancer (SITC)
45 Abstracts Demonstrate the Value of the nCounter Platform for Immuno-Oncology Research Studies Indicate the Clinical Relevance of the Tumor Inflammation Signature for Multiple Immunotherapies SEATTLE , Nov. 09, 2017 (GLOBE NEWSWIRE) --   NanoString Technologies, Inc.
View HTML
Toggle Summary NanoString Technologies Releases Operating Results for Third Quarter of 2017
SEATTLE , Nov. 02, 2017 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ:NSTG), a provider of life science tools for translational research and molecular diagnostic products, today reported financial results for the third quarter of 2017. The results were consistent with the company's
View HTML